innate-pharma.com - IPHA Income before deduction of interest, taxes and amortization
High competition in immuno-oncology and the risks of clinical failures are putting pressure on quotes, however, the EBITDA financial metric on the GURU.Markets time chart shows that the figure remains around 0.00. The business resilience of Innate Pharma S.A. (IPHA) is based on licensing payments and the NK-cell activation platform, while strategic alliances with pharma behemoths provide synergy in drug development.
Innate Pharma - analytical breakdowns and key metrics (IPHA)
- market value and analyst target forecast:
- issuer market value details:
- book capitalization information:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
IPHA - Net Income|Future Net Profit Innate Pharma S.A.|IPHA - P/E Multiple|Future Price to Earnings Multiple innate-pharma.com|IPHA - PEG Multiple|Company Value to EBITDA Innate Pharma|IPHA - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Innate Pharma|IPHA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth innate-pharma.com|IPHA - Earnings per share growth in current year|Net earnings per share change forecast for next year Innate Pharma S.A.
Analysis of all company metrics:Innate Pharma S.A - IPHA
As a European leader in the development of NK-cell antibodies for cancer treatment, Innate Pharma S.A. depends on the effective commercialization of its innovations. The company's consolidated EBITDA reflects operating cash flow before depreciation and taxes, allowing investors to use this chart to assess the business's actual ability to generate cash and promptly identify risks of declining operating margins.
Competitors of Innate Pharma S.A. (IPHA)
NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|Operating profit before deduction of amortization xencor.com XNCR|Compass Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Group Inc REPL|LYEL - Profit before payment of interest, taxes and amortization|PYXS (Pyxis Oncology, Inc.) - Operating profit before amortization|cgen.com (CGEN) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization iobiotech.com (IOBT)|Operating profit before deduction of amortization STRO|INKT - Operating profit before depreciation charges|Operating profit before deduction of amortization HOWL (Werewolf Therapeutics)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|Income before deduction of interest, taxes and amortization CUE|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus - Income before deduction of interest, taxes and amortization|LVTX (LAVA Therapeutics NV) - Operating profit EBITDA|Operating profit EBITDA nextcure.com|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|Gritstone Bio - Operating profit EBITDA|Operating income before deduction of amortization kinetabio.com KA|NexImmune (NEXI) - Profit before payment of interest, taxes and amortization|Operating profit before amortization TSBX|Profit before payment of interest, taxes and amortization Vaccinex, Inc|Operating profit before amortization HARP (Harpoon Therapeutics Corp)
